Search

Your search keyword '"Kado, Nobuhiro"' showing total 17 results
Start Over Author "Kado, Nobuhiro" Publication Year Range Last 3 years
17 results on '"Kado, Nobuhiro"'

6. Discordance of microsatellite instability and mismatch repair immunochemistry occurs depending on the cancer type

Author

Matsubayashi, Hiroyuki, Oishi, Takuma, Sasaki, Keiko, Abe, Masato, Kiyozumi, Yoshimi, Higashigawa, Satomi, Niiya, Fumitaka, Sato, Junya, Ishiwatari, Hirotoshi, Imai, Kenichiro, Hotta, Kinichi, Kishida, Yoshihiro, Takada, Kazunori, Ono, Hiroyuki, Yamazaki, Kenichiro, Yasui, Hirofumi, Kenmotsu, Hirotsugu, Kado, Nobuhiro, Kagawa, Hiroyasu, Shiomi, Akio, Sugiura, Teichi, Bando, Etsuro, Nishimura, Seiichiro, Hatakeyama, Keiichi, Serizawa, Masakuni, Harada, Rina, and Sugino, Takashi

Published
2023
Full Text
View/download PDF

7. Microsatellite instability is biased in Amsterdam II-defined Lynch-related cancer cases with family history but is rare in other cancers: a summary of 1000 analyses

Author

Matsubayashi, Hiroyuki, Higashigawa, Satomi, Kiyozumi, Yoshimi, Oishi, Takuma, Sasaki, Keiko, Ishiwatari, Hirotoshi, Imai, Kenichiro, Hotta, Kinichi, Yabuuchi, Yohei, Ishikawa, Kazuma, Satoh, Tatsunori, Ono, Hiroyuki, Todaka, Akiko, Kawakami, Takeshi, Shirasu, Hiromichi, Yasui, Hirofumi, Sugiura, Teichi, Uesaka, Katsuhiko, Kagawa, Hiroyasu, Shiomi, Akio, Kado, Nobuhiro, Hirashima, Yasuyuki, Kiyohara, Yoshio, Bando, Etsuro, Niwakawa, Masashi, Nishimura, Seiichiro, Aramaki, Takeshi, Mamesaya, Nobuaki, Kenmotsu, Hirotsugu, Horiuchi, Yasue, and Serizawa, Masakuni

Published
2022
Full Text
View/download PDF

8. Proposal for Classifying the Emetogenicity of Oral Anticancer Agents with a Focus on PARP Inhibitors: A Prospective, Observational, Multicenter Study (JASCC-CINV 2002)

Author

Yamamoto, Senri, primary, Tsuchiya, Masami, additional, Iihara, Hirotoshi, additional, Hayasaki, Yoh, additional, Hori, Kyoko, additional, Kumakura, Yasuo, additional, Watanabe, Daichi, additional, Sakai, Hideki, additional, Nakagawa, Satoshi, additional, Kudoh, Akiko, additional, Oishi, Hajime, additional, Kado, Nobuhiro, additional, Go, Makiko, additional, Mashima, Kota, additional, Uchida, Takashi, additional, Yasue, Moeka, additional, Maeda, Akimitsu, additional, Nishino, Kimihiro, additional, Matsumoto, Koji, additional, Sato, Shinya, additional, Ueda, Yutaka, additional, Tomio, Kensuke, additional, Hayashi, Katsuhisa, additional, Takenaka, Motoki, additional, Mori, Masahiko, additional, Kajiyama, Hiroaki, additional, Bomoto, Yoshimasa, additional, Suzuki, Shiro, additional, Ishihara, Takuma, additional, Suzuki, Akio, additional, and Abe, Masakazu, additional

Published
2024
Full Text
View/download PDF

9. A Japanese Family Meeting the Clinical Diagnostic Criteria for MEN1 with a MEN1 Variant of Uncertain Significance

Author

Matsubayashi, Hiroyuki, primary, Kiyozumi, Yoshimi, additional, Harada, Rina, additional, Mukaigawa, Takashi, additional, Sugiura, Teichi, additional, Ishiwatari, Hirotoshi, additional, Sato, Junya, additional, Niiya, Fumitaka, additional, Nakashima, Kazuaki, additional, Kado, Nobuhiro, additional, Nishimura, Seiichiro, additional, Honda, Goichi, additional, and Ohike, Nobuyuki, additional

Published
2023
Full Text
View/download PDF

10. Genetic medicine in companion diagnostics of germline BRCA testing of Japanese pancreatic cancer patients

Author

Matsubayashi, Hiroyuki, primary, Todaka, Akiko, additional, Kawakami, Takeshi, additional, Hamauchi, Satoshi, additional, Yokota, Tomoya, additional, Higashigawa, Satomi, additional, Kiyozumi, Yoshimi, additional, Harada, Rina, additional, Kado, Nobuhiro, additional, Nishimura, Seiichiro, additional, Ishiwatari, Hirotoshi, additional, Sato, Junya, additional, Niiya, Fumitaka, additional, Ono, Hiroyuki, additional, Sugiura, Teiichi, additional, Sasaki, Keiko, additional, Yasui, Hirofumi, additional, and Yamazaki, Kentaro, additional

Published
2022
Full Text
View/download PDF

11. Discordance of microsatellite instability and mismatch repair immunochemistry occurs depending on the cancer type

Author

Matsubayashi, Hiroyuki, primary, Oishi, Takuma, additional, Sasaki, Keiko, additional, Abe, Masato, additional, Kiyozumi, Yoshimi, additional, Higashigawa, Satomi, additional, Niiya, Fumitaka, additional, Sato, Junya, additional, Ishiwatari, Hirotoshi, additional, Imai, Kenichiro, additional, Hotta, Kinichi, additional, Kishida, Yoshihiro, additional, Takada, Kazunori, additional, Ono, Hiroyuki, additional, Yamazaki, Kenichiro, additional, Yasui, Hirofumi, additional, Kenmotsu, Hirotsugu, additional, Kado, Nobuhiro, additional, Kagawa, Hiroyasu, additional, Shiomi, Akio, additional, Sugiura, Teichi, additional, Bando, Etsuro, additional, Nishimura, Seiichiro, additional, Hatakeyama, Keiichi, additional, Serizawa, Masakuni, additional, Harada, Rina, additional, and Sugino, Takashi, additional

Published
2022
Full Text
View/download PDF

12. Present status of germline findings in precision medicine for Japanese cancer patients: issues in the current system

Author

Higashigawa, Satomi, primary, Matsubayashi, Hiroyuki, additional, Kiyozumi, Yoshimi, additional, Kado, Nobuhiro, additional, Nishimura, Seiichiro, additional, Oishi, Takuma, additional, Sugino, Takashi, additional, Fushiki, Kunihiro, additional, Shirasu, Hiromichi, additional, Yasui, Hirofumi, additional, Mamesaya, Nobuaki, additional, Fukuzaki, Naomi, additional, Kunitomo, Kana, additional, Horiuchi, Yasue, additional, Kenmotsu, Hirotsugu, additional, and Serizawa, Masakuni, additional

Published
2022
Full Text
View/download PDF

13. Genetic medicine in companion diagnostics of germline BRCAtesting of Japanese pancreatic cancer patients

Author

Matsubayashi, Hiroyuki, Todaka, Akiko, Kawakami, Takeshi, Hamauchi, Satoshi, Yokota, Tomoya, Higashigawa, Satomi, Kiyozumi, Yoshimi, Harada, Rina, Kado, Nobuhiro, Nishimura, Seiichiro, Ishiwatari, Hirotoshi, Sato, Junya, Niiya, Fumitaka, Ono, Hiroyuki, Sugiura, Teiichi, Sasaki, Keiko, Yasui, Hirofumi, and Yamazaki, Kentaro

Abstract

In 2021, Japan’s national health insurance made germline BRCA(g.BRCA) testing available to unresectable pancreatic cancer (PC) patients as a companion diagnostic (CD) of the PARP inhibitor. This study investigated the incidence of the g.BRCAvariant (g.BRCAv.) and the status of the genetic medicine associated with its testing. A total of 110 PC patients underwent the testing, five of whom (4.5%) had a deleterious g.BRCA2v. (all truncations) but no g.BRCA1v. The turnaround time (TAT) to the doctors was 13 days, and to the patients, 17 days. A higher incidence of a BRCA-related family history and a shorter TAT were seen in the g.BRCAv. patients, but they were insignificant (p= 0.085 and p= 0.059, respectively). Genetic counseling was not performed for three g.BRCA2v. patients because two of them had no accessible relatives and one died of the cancer before the genetic report was completed. Two families underwent generic counseling and testing based on the patient’s genetic data. g.BRCAv. is recognized in a small fraction of PC cases, and the following genetic counseling is done more for the relatives than for the patients. TAT was constant and did not affect much on the genetic counseling, but the earlier testing is expected for patients with a deadly cancer.

Published
2023
Full Text
View/download PDF

14. A Japanese case of ovarian mucinous adenocarcinoma with germline double variants of MSH2and BRCA2

Author

Harada, Rina, Matsubayashi, Hiroyuki, Kiyozumi, Yoshimi, Kobayashi, Haruki, Mitsuya, Koichi, Imai, Kenichiro, Yamamoto, Yoichi, Oishi, Takuma, Kado, Nobuhiro, Nishimura, Seiichiro, Higashigawa, Satomi, and Serizawa, Masakuni

Abstract

Germline double heterozygosity (GDH) is rarely reported in cases of inherited cancer syndromes, and GDH of a mismatch repairgene and BRCAhas never been reported in Japan. Nonetheless, the current report demonstrates a case of ovarian mucinous adenocarcinoma with initiated Lynch syndrome (LS)-related surveillance because of a known germline MSH2variant. Six and a half years after oophorectomy, multiple tumors developed in the patient’s lungs, bones, and lymph nodes, and histology results confirmed mucinous adenocarcinoma. Systemic chemotherapy including an anti-PD-L1 antibody was effective for >1 year, but brain metastases developed. Pathology of the brain tumors showed mucinous adenocarcinoma without expression of MSH2 and MSH6, while multi-gene panel testing demonstrated not only high microsatellite instability and a high tumor mutation burden, but also germline BRCA2variants. Further, germline testing in relatives confirmed both variants were from the paternal line, from which many LS-related cancers develop, but not BRCA-related cancer.

Published
2023
Full Text
View/download PDF

15. A Japanese case of familial malignant melanoma with germline CDK4variant incidentally diagnosed by cancer genome profiling

Author

Kiyozumi, Yoshimi, Goto, Keisuke, Yoshikawa, Shusuke, Kiyohara, Yoshio, Tsushima, Takahiro, Kado, Nobuhiro, Nishimura, Seiichiro, Higashigawa, Satomi, Harada, Rina, Kunitomo, Kana, Fukuzaki, Naomi, and Matsubayashi, Hiroyuki

Abstract

Familial malignant melanoma (FMM) is a hereditary tumor that is quite rare in Japan; to date, the germline CDK4variant has scarcely been reported around the world. Thus, we report on a woman with FMM who developed salivary gland cancer, for which a germline pathogenic variant of CDK4was incidentally identified through comprehensive genomic profiling. She had a history of multiple atypical nevi and a facial melanoma since her 30 s and multiple family histories of melanoma; however, none of her relatives were aware of its heredity. Genetic counseling and skin surveillance were performed. Precision medicine for cancer can discover this rare genetic syndrome and provides us with the opportunity to manage the health of patients and their relatives.

Published
2023
Full Text
View/download PDF

16. A Japanese Family Meeting the Clinical Diagnostic Criteria for MEN1 with a MEN1 Variant of Uncertain Significance.

Author

Matsubayashi H, Kiyozumi Y, Harada R, Mukaigawa T, Sugiura T, Ishiwatari H, Sato J, Niiya F, Nakashima K, Kado N, Nishimura S, Honda G, and Ohike N

Subjects
Aged, Humans, Male, Germ-Line Mutation, Japan, Proto-Oncogene Proteins genetics, East Asian People genetics, Multiple Endocrine Neoplasia Type 1 diagnosis, Multiple Endocrine Neoplasia Type 1 genetics, Multiple Endocrine Neoplasia Type 1 pathology, Neuroendocrine Tumors pathology, Pituitary Neoplasms
Abstract

Multiple gastroenteric, pancreatic, and pituitary neuroendocrine neoplasms (NENs) were diagnosed in a 74-year-old man with a history of primary hyperparathyroidism (PHPT). Germline testing demonstrated a variant of MEN1 (c.1694T>A, p.L565Q), whose pathogenicity was classified as a variant of uncertain significance (VUS) according to the ACMG/AMP guidelines. The same germline variant was detected in the patient's son and daughter, who also showed PHPT or hypercalcemia and met the clinical diagnostic criteria for multiple endocrine neoplasia type 1 (MEN1). During surveillance of the son, multiple pancreatic tumors suggestive of NENs were detected. The pathogenicity of the current MEN1 variant was re-evaluated as likely pathogenic, based on additional family data.

Published
2024
Full Text
View/download PDF

17. Changes in HPV16/18 Prevalence among Unvaccinated Women with Cervical Intraepithelial Neoplasia in Japan: Assessment of Herd Effects following the HPV Vaccination Program.

Author

Onuki M, Yamamoto K, Yahata H, Kanao H, Horie K, Konnai K, Nio A, Takehara K, Kamiura S, Tsuda N, Takei Y, Shigeta S, Nakai H, Yoshida H, Motohara T, Kato T, Nakamura K, Hamanishi J, Tasaka N, Ishikawa M, Kado N, Taira Y, Mori M, Iwata T, Takahashi F, Kukimoto I, Yoshikawa H, Yaegashi N, Matsumoto K, and For The Mint Study Group

Abstract

Since the human papillomavirus (HPV) vaccination program for Japanese girls aged 12-16 years began in 2010, vaccination uptake has been low in women born before 1993 but high (approximately 70%) in those born during 1994-1999. We previously compared the prevalence of vaccine types HPV16 and HPV18 in cervical intraepithelial neoplasia grade 1-3 (CIN1-3) or adenocarcinoma in situ (AIS) between vaccinated and unvaccinated cohorts and found direct protection effects among vaccinated women in Japan. In this study, we focused on changes in HPV16/18 prevalence among "unvaccinated" cohorts with CIN/AIS. We analyzed HPV16/18 prevalence among 5051 unvaccinated women aged <40 years, newly diagnosed with CIN/AIS during 2012-2021 for time trends. Declining trends in HPV16/18 prevalence over 9 years were observed in CIN1 (36.0-10.0%, P trend = 0.03) and CIN2-3/AIS (62.5-36.4%, P trend = 0.07) among women aged <25 years. HPV16/18 prevalence in CIN1 and CIN2-3/AIS diagnosed at age 20-24 years was lower in 1994-1999 birth cohorts compared with 1988-1993 birth cohorts (4.5% vs. 25.7% for CIN1 and 40.0% vs. 58.1% for CIN2-3/AIS, both p = 0.04). Significant reduction in HPV16/18 prevalence among young unvaccinated women with CIN1 and CIN2-3/AIS suggests herd effects of HPV vaccination in Japan.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results